TY - JOUR T1 - Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany JF - European Respiratory Journal JO - Eur Respir J SP - 1826 LP - 1829 DO - 10.1183/13993003.00811-2015 VL - 46 IS - 6 AU - Lara J. Wolfson AU - Judith Gibbert AU - Daniel Wirth AU - Roland Diel Y1 - 2015/12/01 UR - http://erj.ersjournals.com/content/46/6/1826.abstract N2 - The emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has re-established TB as a major worldwide health concern [1–3]. Compared with conventional TB drug regimens, treatments for MDR-TB and XDR-TB are more toxic, expensive and associated with poorer outcomes [3, 4]. In Germany, 102 (2.4%) of the 4318 TB cases reported for 2013 were MDR-TB, including 10 patients with XDR-TB [5], increasing from 54 (1.8%) cases in 2011 [5, 6]. An important factor behind the increase in Germany is migration, with more cases occurring in patients from the former Soviet Union than in native Germans [5].Adding bedaquiline to the background regimen is likely to be cost-effective for treatment of MDR/XDR-TB in Germany http://ow.ly/SwMdv ER -